Drägerwerk KGaA Valuation
Is DRW3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of DRW3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: DRW3 (€43.75) is trading below our estimate of fair value (€122.17)
Significantly Below Fair Value: DRW3 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for DRW3?
Key metric: As DRW3 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is DRW3's PE Ratio? | |
|---|---|
| PE Ratio | 7.2x |
| Earnings | €113.44m |
| Market Cap | €792.54m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.3x |
| Enterprise Value/EBITDA | 4x |
| PEG Ratio | 3.6x |
Price to Earnings Ratio vs Peers
How does DRW3's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 28.1x | ||
2291 LEPU ScienTech Medical Technology (Shanghai) | 27.3x | n/a | HK$6.1b |
ARJO B Arjo | 18.6x | 25.1% | SEK 9.4b |
300206 Edan Instruments | 45x | n/a | CN¥7.1b |
2172 MicroPort NeuroScientific | 21.5x | 22.5% | HK$5.1b |
DRW3 Drägerwerk KGaA | 7.2x | 2.0% | €792.5m |
Price-To-Earnings vs Peers: DRW3 is good value based on its Price-To-Earnings Ratio (7.2x) compared to the peer average (27.9x).
Price to Earnings Ratio vs Industry
How does DRW3's PE Ratio compare vs other companies in the European Medical Equipment Industry?
| 3 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 3 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: DRW3 is good value based on its Price-To-Earnings Ratio (7.2x) compared to the European Medical Equipment industry average (29.8x).
Price to Earnings Ratio vs Fair Ratio
What is DRW3's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 7.2x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate DRW3's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €43.75 | €58.60 +33.9% | 13.8% | €70.00 | €47.00 | n/a | 5 |
| Nov ’25 | €45.25 | €57.00 +26.0% | 14.5% | €70.00 | €47.00 | n/a | 4 |
| Oct ’25 | €47.30 | €58.00 +22.6% | 18.1% | €70.00 | €42.00 | n/a | 4 |
| Sep ’25 | €45.95 | €58.00 +26.2% | 18.1% | €70.00 | €42.00 | n/a | 4 |
| Aug ’25 | €47.70 | €58.00 +21.6% | 18.1% | €70.00 | €42.00 | n/a | 4 |
| Jul ’25 | €49.80 | €58.00 +16.5% | 18.1% | €70.00 | €42.00 | n/a | 4 |
| Jun ’25 | €50.00 | €57.50 +15.0% | 17.8% | €70.00 | €42.00 | n/a | 4 |
| May ’25 | €50.30 | €57.50 +14.3% | 17.8% | €70.00 | €42.00 | n/a | 4 |
| Apr ’25 | €51.20 | €56.25 +9.9% | 15.7% | €65.00 | €42.00 | n/a | 4 |
| Mar ’25 | €46.95 | €56.25 +19.8% | 15.7% | €65.00 | €42.00 | n/a | 4 |
| Feb ’25 | €47.40 | €56.25 +18.7% | 15.7% | €65.00 | €42.00 | n/a | 4 |
| Jan ’25 | €51.90 | €54.00 +4.0% | 18.3% | €65.00 | €38.00 | n/a | 4 |
| Dec ’24 | €52.00 | €54.00 +3.8% | 18.3% | €65.00 | €38.00 | n/a | 4 |
| Nov ’24 | €47.80 | €50.28 +5.2% | 20.0% | €65.00 | €38.00 | €45.25 | 4 |
| Oct ’24 | €42.35 | €50.28 +18.7% | 20.0% | €65.00 | €38.00 | €47.30 | 4 |
| Sep ’24 | €44.90 | €50.28 +12.0% | 20.0% | €65.00 | €38.00 | €45.95 | 4 |
| Aug ’24 | €45.65 | €49.78 +9.0% | 21.4% | €65.00 | €36.00 | €47.70 | 4 |
| Jul ’24 | €43.60 | €47.53 +9.0% | 22.5% | €65.00 | €36.00 | €49.80 | 4 |
| Jun ’24 | €42.20 | €55.62 +31.8% | 33.8% | €88.00 | €36.00 | €50.00 | 5 |
| May ’24 | €51.30 | €55.62 +8.4% | 33.8% | €88.00 | €36.00 | €50.30 | 5 |
| Apr ’24 | €42.45 | €53.28 +25.5% | 38.2% | €88.00 | €36.00 | €51.20 | 4 |
| Mar ’24 | €41.15 | €52.81 +28.3% | 39.0% | €88.00 | €36.00 | €46.95 | 4 |
| Feb ’24 | €41.15 | €52.81 +28.3% | 39.0% | €88.00 | €36.00 | €47.40 | 4 |
| Jan ’24 | €43.50 | €55.08 +26.6% | 34.6% | €88.00 | €42.00 | €51.90 | 4 |
| Dec ’23 | €43.60 | €55.08 +26.3% | 34.6% | €88.00 | €42.00 | €52.00 | 4 |
| Nov ’23 | €41.95 | €55.08 +31.3% | 34.6% | €88.00 | €42.00 | €47.80 | 4 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
CVS Health
US$75.5b
Provides health solutions in the United States.
CVS
US$56.25
7D
3.8%
1Y
-9.1%
Siemens Healthineers
€57.0b
Through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers worldwide.
SHL
€50.96
7D
3.9%
1Y
-3.9%
DENTSPLY SIRONA
US$3.9b
Manufactures and sells various dental products and technologies worldwide.
XRAY
US$18.61
7D
4.1%
1Y
-35.9%